JNJ

227.97

+0.19%↑

ABT

92.08

+0.26%↑

MDT

83.08

-0.81%↓

113.7

+0.94%↑

VEEV

155.61

+0.75%↑

JNJ

227.97

+0.19%↑

ABT

92.08

+0.26%↑

MDT

83.08

-0.81%↓

113.7

+0.94%↑

VEEV

155.61

+0.75%↑

JNJ

227.97

+0.19%↑

ABT

92.08

+0.26%↑

MDT

83.08

-0.81%↓

113.7

+0.94%↑

VEEV

155.61

+0.75%↑

JNJ

227.97

+0.19%↑

ABT

92.08

+0.26%↑

MDT

83.08

-0.81%↓

113.7

+0.94%↑

VEEV

155.61

+0.75%↑

JNJ

227.97

+0.19%↑

ABT

92.08

+0.26%↑

MDT

83.08

-0.81%↓

113.7

+0.94%↑

VEEV

155.61

+0.75%↑

Strona główna・Stock List・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Closed

1.26 -0.79

Buy Sell

Overview

Share price change

24h

Current

Min

1.25

Max

1.3

Key metrics
By Trading Economics
Income	2.7M -24M
EPS	-0.354
Employees	49
EBITDA	-5.3M -28M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+106.98% upside

Dividends
By Dow Jones
Next Earnings	7 maj 2026

Market Stats
By TradingEconomics
Market Cap	-1.2M 80M
Previous open	2.05
Previous close	1.26

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

1.43 / 1.6 Support & Resistance

Pliant Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

24 kwi 2026, 00:00 UTC

Earnings

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

24 kwi 2026, 00:00 UTC

Earnings

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

23 kwi 2026, 23:47 UTC

Market Talk

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

23 kwi 2026, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 kwi 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

23 kwi 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

23 kwi 2026, 23:13 UTC

Acquisitions, Mergers, Takeovers

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

23 kwi 2026, 22:33 UTC

Earnings

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

23 kwi 2026, 22:17 UTC

Earnings

PLS Executed Offtake Agreement With Ronbay

23 kwi 2026, 22:17 UTC

Earnings

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

23 kwi 2026, 22:16 UTC

Earnings

PLS Commences Commissioning of Midstream Demonstration Plant

23 kwi 2026, 22:15 UTC

Earnings

PLS Group Reaffirms FY26 Guidance for All Metrics

23 kwi 2026, 22:14 UTC

Earnings

PLS Group 3Q Cash Margin From Operations A$461M at March 31

23 kwi 2026, 22:14 UTC

Earnings

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

23 kwi 2026, 22:13 UTC

Earnings

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

23 kwi 2026, 22:12 UTC

Earnings

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

23 kwi 2026, 22:12 UTC

Earnings

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

23 kwi 2026, 22:11 UTC

Earnings

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

23 kwi 2026, 22:10 UTC

Earnings

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

23 kwi 2026, 22:09 UTC

Earnings

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

23 kwi 2026, 22:08 UTC

Earnings

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

23 kwi 2026, 22:04 UTC

Earnings

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

23 kwi 2026, 21:56 UTC

Market Talk

Earnings

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

23 kwi 2026, 21:48 UTC

Acquisitions, Mergers, Takeovers

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

23 kwi 2026, 21:27 UTC

Earnings

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

23 kwi 2026, 21:25 UTC

Earnings

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

23 kwi 2026, 21:24 UTC

Earnings

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

23 kwi 2026, 21:24 UTC

Earnings

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

23 kwi 2026, 21:21 UTC

Earnings

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

23 kwi 2026, 21:21 UTC

Earnings

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Peer Comparison

Price change

Pliant Therapeutics Inc Forecast

Price Target

By TipRanks

106.98% upside

12 Months Forecast

Average 2.67 USD 106.98%

High 3 USD

Low 2 USD

Based on 5 Wall Street analysts offering 12 month price targets forPliant Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Pliant Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.43 / 1.6Support & Resistance

Recent bearish events outweigh bullish events.

There is one bearish event.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.